Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NITRO trial of neoadjuvant intravitreal ranibizumab in high-risk ocular melanoma
2011-000961-10Phase 2Terminated
- Sponsor
- Royal Liverpool & Broadgreen University Hospitals
- Start
- Sep 2011
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ranibizumab in intraocular melanoma and eye melanoma, sponsored by Royal Liverpool & Broadgreen University Hospitals. Primary endpoint: Response rate. Started Sep 2011; status: terminated.
02
Drugs
ranibizumab
03
Conditions
intraocular melanomaeye melanoma
Beyond the preview
Go deeper on 2011-000961-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000961-10.